down arrow

ImmunoPrecise Antibodies Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA45257F2008
USD
2.07
0.32 (18.29%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
ImmunoPrecise Antibodies Ltd.
Spero Therapeutics, Inc.
Rani Therapeutics Holdings, Inc.
Shattuck Labs, Inc.
Aspira Women's Health, Inc.
HOOKIPA Pharma, Inc.
Solid Biosciences, Inc.
Instil Bio, Inc.
CEL-SCI Corp.
Intensity Therapeutics, Inc.
OKYO Pharma Ltd.
Why is ImmunoPrecise Antibodies Ltd. ?
1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 368.59%, its profits have risen by 31.3%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ImmunoPrecise Antibodies Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
ImmunoPrecise Antibodies Ltd.
474.68%
0.56
128.47%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
10.82%
EBIT Growth (5y)
-199.66%
EBIT to Interest (avg)
-11.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.45
Sales to Capital Employed (avg)
0.59
Tax Ratio
9.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
7.08%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.77
EV to EBIT
-2.19
EV to EBITDA
-3.66
EV to Capital Employed
2.40
EV to Sales
1.32
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-109.36%
ROE (Latest)
-41.78%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
NET PROFIT(HY)

Higher at USD -1.76 MM

RAW MATERIAL COST(Y)

Fallen by -69.2% (YoY

NET SALES(Q)

Highest at USD 4.91 MM

OPERATING PROFIT(Q)

Highest at USD -0.39 MM

OPERATING PROFIT MARGIN(Q)

Highest at -8.04 %

PRE-TAX PROFIT(Q)

Highest at USD -1.34 MM

EPS(Q)

Highest at USD -0.03

-3What is not working for the Company
ROCE(HY)

Lowest at -102.69%

INVENTORY TURNOVER RATIO(HY)

Lowest at 6.04 times

Here's what is working for ImmunoPrecise Antibodies Ltd.
Net Profit
Higher at USD -1.76 MM
than preceding 12 month period ended Apr 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Net Profit
At USD -1.76 MM has Grown at 60%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Net Sales
Highest at USD 4.91 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD -0.39 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at -8.04 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at USD -1.34 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Pre-Tax Profit
At USD -1.34 MM has Grown at 52.13%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

EPS
Highest at USD -0.03
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost
Fallen by -69.2% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for ImmunoPrecise Antibodies Ltd.
Inventory Turnover Ratio
Lowest at 6.04 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."